Furthermore, in patients with X-linked myotubular myopathy, the investigational therapeutic MTM1 (myotubularin) named AT132 using an AAV8 resulted in four deaths showing liver dysfunction from 3–4 weeks after receiving AT132. The gene discussed is MTM1; the disease is Decreased liver function.